329-56-6
329-56-6
Chemical Structure
Norepinephrine hydrochloride
Synonym(s): Levarterenol hydrochloride; L-Noradrenaline hydrochloride
- CAS No.: 329-56-6
- Formula:C8H12ClNO3
- Molecular Weight:205.64
IUPAC Name: (R)-4-(2-amino-1-hydroxyethyl)benzene-1,2-diol hydrochloride
InChIKey: FQTFHMSZCSUVEU-QRPNPIFTSA-N
SMILES: OC1=CC=C([C@@H](O)CN)C=C1O.Cl
Biological Activity: Norepinephrine (Levarterenol; L-Noradrenaline) hydrochloride is a potent adrenergic receptor (AR) agonist. Norepinephrine activates α1, α2, β1 receptors[1][2][3][4].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Norepinephrine hydrochloride | 99.45% | Norepinephrine (Levarterenol; L-Noradrenaline) hydrochloride is a potent adrenergic receptor (AR) agonist. Norepinephrine activates α1, α2, β1 receptors. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Norepinephrine hydrochloride (Standard) | 99.58% | Norepinephrine (hydrochloride) (Standard) is the analytical standard of Norepinephrine (hydrochloride). This product is intended for research and analytical applications. Norepinephrine (Levarterenol; L-Noradrenaline) hydrochloride is a potent adrenergic receptor (AR) agonist. Norepinephrine activates α1, α2, β1 receptors. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Brian P Ramos, et al. Adrenergic pharmacology and cognition: focus on the prefrontal cortex. Pharmacol Ther. 2007 Mar;113(3):523-36. [Content Brief]
- [2]. MacGregor DA, et al. Relative efficacy and potency of beta-adrenoceptor agonists for generating cAMP in human lymphocytes. Chest. 1996 Jan;109(1):194-200. [Content Brief]
- [3]. Littlejohn NK, et al. Suppression of Resting Metabolism by the Angiotensin AT2 Receptor. Cell Rep. 2016 Aug 9;16(6):1548-60. [Content Brief]
- [4]. Xinyu Xu, et al. Binding pathway determines norepinephrine selectivity for the human β 1 AR over β 2 AR. Cell Res. 2021 May;31(5):569-579. [Content Brief]
